| scholarly article | Q13442814 |
| P50 | author | José M González-Navajas | Q39836999 |
| Pedro Zapater | Q39837042 | ||
| Rubén Francés | Q59698583 | ||
| Laura Sempere | Q60316164 | ||
| P2093 | author name string | Michael Scharl | |
| Gerhard Rogler | |||
| Reiner Wiest | |||
| Ernst Holler | |||
| Ana Gutiérrez | |||
| José Such | |||
| Isabel Almenta | |||
| P2860 | cites work | Inflammatory Bowel Disease | Q22248115 |
| A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease | Q22251291 | ||
| Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB | Q24290546 | ||
| Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection | Q24292675 | ||
| Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls | Q24550675 | ||
| Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci | Q24618592 | ||
| Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis | Q24656576 | ||
| Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease | Q28201834 | ||
| Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 | ||
| Infliximab maintenance therapy for fistulizing Crohn's disease | Q28246982 | ||
| Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis | Q29614481 | ||
| A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 | Q29614873 | ||
| Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant | Q33375721 | ||
| Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 | ||
| ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis | Q34258672 | ||
| Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study | Q34523337 | ||
| From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation | Q35787421 | ||
| Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? | Q35966079 | ||
| Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota | Q36209737 | ||
| Innate and adaptive immunity through autophagy | Q36896712 | ||
| Eating for good health: linking autophagy and phagocytosis in host defense | Q37190857 | ||
| Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies | Q37367325 | ||
| The evolving epidemiology of inflammatory bowel disease. | Q37435736 | ||
| Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review | Q37496554 | ||
| What is the optimal therapy for Crohn's disease: step-up or top-down? | Q37720746 | ||
| New IBD genetics: common pathways with other diseases. | Q37837253 | ||
| Conventional medical management of inflammatory bowel disease | Q37870434 | ||
| Therapeutic drug monitoring of biologics for inflammatory bowel disease | Q37948705 | ||
| CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation | Q38321426 | ||
| Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology | Q40390478 | ||
| The molecular classification of the clinical manifestations of Crohn's disease | Q40651190 | ||
| Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease | Q45758087 | ||
| Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease | Q46504948 | ||
| Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. | Q52970473 | ||
| Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. | Q53540951 | ||
| Infliximab, azathioprine, or combination therapy for Crohn's disease | Q56988763 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 272-280 | |
| P577 | publication date | 2013-02-01 | |
| P1433 | published in | Gut | Q5621669 |
| P1476 | title | Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease | |
| P478 | volume | 63 |
| Q37670529 | A Potential Role of Salmonella Infection in the Onset of Inflammatory Bowel Diseases |
| Q38367539 | ATG16L1 and IL23R variants and genetic susceptibility to crohn's disease: mode of inheritance based on meta-analysis of genetic association studies |
| Q28082887 | ATG16L1: A multifunctional susceptibility factor in Crohn disease |
| Q34239249 | Adipose-tissue and intestinal inflammation - visceral obesity and creeping fat |
| Q38194867 | Advances in IBD genetics |
| Q34425509 | Anatomical localization of commensal bacteria in immune cell homeostasis and disease |
| Q86264935 | Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease |
| Q64262361 | Antibiotics in inflammatory bowel diseases: do we know what we're doing? |
| Q89884711 | Association between variants of the autophagy related gene ATG16L1 in inflammatory bowel diseases and clinical statues |
| Q93272821 | Autophagy-mediated regulation of neutrophils and clinical applications |
| Q26852238 | Bacterial translocation - impact on the adipocyte compartment |
| Q92187244 | Food additives: Assessing the impact of exposure to permitted emulsifiers on bowel and metabolic health - introducing the FADiets study |
| Q34037058 | Genetic and functional profiling of Crohn's disease: autophagy mechanism and susceptibility to infectious diseases |
| Q58862198 | Genetic polymorphism inATG16L1gene influences the response to adalimumab in Crohn's disease patients |
| Q53170686 | Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. |
| Q35575495 | IBD and the gut microbiota--from bench to personalized medicine |
| Q47844376 | IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA. |
| Q39742575 | Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn's Disease |
| Q64112334 | Increased risk of chronic fatigue syndrome in patients with inflammatory bowel disease: a population-based retrospective cohort study |
| Q36252769 | Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease |
| Q35723593 | Microbial Population Differentials between Mucosal and Submucosal Intestinal Tissues in Advanced Crohn's Disease of the Ileum |
| Q54236491 | Molecular Recognition of Muramyl Dipeptide Occurs in the Leucine-rich Repeat Domain of Nod2. |
| Q46269946 | NOD2 and bacterial recognition as therapeutic targets for Crohn's disease. |
| Q37585753 | Pathophysiology of Intestinal Na+/H+ exchange |
| Q92677838 | Physiology of Electrolyte Transport in the Gut: Implications for Disease |
| Q92377022 | Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn's Disease-A Systematic Review and Gene Ontology Analysis |
| Q26745721 | Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease |
| Q43988900 | Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse |
| Q42093953 | Role of HLA typing on Crohn's disease pathogenesis |
| Q35721537 | Select a suitable treatment strategy for Crohn's disease: step-up or top-down. |
| Q41630782 | The impact of bacterial DNA translocation on early postoperative outcomes in Crohn's patients undergoing abdominal surgery. |
| Q35538922 | The intestinal microbiota: its role in health and disease |
Search more.